AstraZeneca Lynparza Breast Cancer Treatment Is Recommended for EU Approval
27 Junho 2022 - 3:50AM
Dow Jones News
By Joe Hoppe
AstraZeneca PLC said Monday that its Lynparza treatment has been
recommended for approval in the European Union by the Committee for
Medicinal Products for Human Use for early breast cancer treatment,
after positive Phase 3 results.
The Anglo-Swedish pharmaceutical company said the treatment is
the first PARP inhibitor--a type of targeted cancer drug--to
improve overall survival in early-stage, high-risk breast
cancer.
Lynparza has been recommended for marketing authorization as a
monotherapy or in combination with endocrine therapy, specifically
for treating adults with germline BRCA1/2 mutations, or gBRCAm,
with HER2-negative high-risk early breast cancers that have
previously been treated with chemotherapy.
The decision was based on positive results from a trial,
published in June 2021. The treatment demonstrated a statistically
significant and clinically meaningful improvement in invasive
disease-free survival, reducing the risk of invasive breast cancer
recurrences, new cancers, or death by 42% when compared with a
placebo, it said. The drug's safety and tolerability in the trial
was also in line with prior results, it added.
The treatment was approved in the U.S. for treating gBRCAm,
HER2-negative high-risk early breast cancer in March.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
June 27, 2022 02:35 ET (06:35 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024